Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00476294 · ClinicalTrials.gov registry record
Long-Term Follow Up Study for AMD3100 Patients
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- 7
- Enrollment target
NCT00476294: Completed study, sponsored by M.D. Anderson Cancer Center.
NCT00476294 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00476294 has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
Objectives: The objective of this long-term observational study is to assess progression-free survival and overall survival for a period of five years following the first dose of study treatment (placebo or plerixafor \[AMD3100\]) in protocol AMD3100-3102. Patients that received at least 1 dose of study treatment (placebo or plerixafor) in the multicenter, randomized, double-blind, placebo-controlled AMD3100-3102 study, which was designed to evaluate plerixafor plus granulocyte colony stimulating factor (G-CSF) versus placebo plus G-CSF to mobilize hematopoietic stem cells for autologous transplantation of Multiple Myeloma (MM) patients are eligible.
Primary Outcome
Progression-free survival defined as number of participants without disease progression at five years following the first dose of study treatment (placebo or plerixafor \[AMD3100\]).
Interventions
- OTHER Telephone Questionnaire
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2006-10 |
| Est. Completion | 2012-07 |
What the finished NCT00476294 record still lists
NCT00476294 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 7 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Telephone Questionnaire is the first listed.
NCT00476294 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00476294 about?
NCT00476294 is a clinical study titled "Long-Term Follow Up Study for AMD3100 Patients". Objectives: The objective of this long-term observational study is to assess progression-free survival and overall survival for a period of five years following the first dose of study treatment (placebo or plerixafor \[AMD3100\]) in protocol AMD3100-3102. Patients that received at least 1 dose of ...
What is the current status of trial NCT00476294?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2006-10. Estimated completion is 2012-07.
What interventions are being tested in trial NCT00476294?
The interventions under investigation include: Telephone Questionnaire (OTHER).
Who is sponsoring clinical trial NCT00476294?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia